Simpler Grants.gov #HT942526PRMRPCTA

FY26 Peer Reviewed Medical Research Program Clinical Trial Award Solicitation

This opportunity seeks proposals for clinical trials under the FY26 Peer Reviewed Medical Research Program (PRMRP), managed by the Dept. of the Army and the Defense Health Agency: - Government Buyer: - Dept. of the Army, US Army Medical Research Acquisition Activity (USAMRAA) - Defense Health Agency (DHA), Defense Health Agency Research and Development (DHA R&D), and Defense Health Agency Contracting Activity (DHACA) - Products/Services Requested: - Implementation of clinical trials addressing diseases or conditions specified in FY26 PRMRP topic areas - Options for 'Clinical Trial Only' or 'Clinical Trial with Planning Phase' (includes regulatory and planning activities) - No animal studies; all preclinical laboratory work must be completed before award - Funding Levels and Quantities: - Planning Phase: up to $800,000, maximum 12 months - Level 1 (Phase 0/1 or 300 participants): up to $20M, maximum 4 years - Total program funding: approximately $94.5M, with about 9 awards anticipated - Unique/Notable Requirements: - Rapid clinical trial execution and regulatory compliance - Relevance to military service members, veterans, and families - Eligible applicants are unrestricted; no cost sharing required - Funding instrument may be a cooperative agreement or grant - No specific OEMs or commercial vendors are named, as this is a research grant opportunity for clinical trial services.

Description

The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials aimed at significantly impacting the treatment and management of diseases or conditions specified in the FY26 PRMRP topic areas and strategic goals. The award supports two application categories based on the clinical trial planning phase: Clinical Trial Only and Clinical Trial with Planning Phase, with the latter supporting final regulatory and planning activities prior to trial initiation. The program funds three levels of clinical trials based on phase and participant number, with total funding of approximately $94.5 million to support about 9 awards. The maximum performance period is 4 years for clinical trials and 12 months for planning phases, with awards funded by FY26 funds expiring on September 30, 2032.

View original listing